Vitiligo is a commonly observed irAE with ICI treatment in patients with melanoma and it is more frequently associated with the use of PD-1 inhibitors (nivolumab and pembrolizumab) compared to the use of CTLA-4 inhibitors (ipilimumab) [71]. Here, PDCD1 is linked to melanoma.